Published in Trends Pharmacol Sci on January 31, 2009
Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov (2011) 4.16
Virtual screening: an endless staircase? Nat Rev Drug Discov (2010) 2.26
ElectroShape: fast molecular similarity calculations incorporating shape, chirality and electrostatics. J Comput Aided Mol Des (2010) 1.14
Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04
Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface (2012) 1.01
Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol (2009) 1.01
Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases. J R Soc Interface (2009) 1.00
Alpha shapes applied to molecular shape characterization exhibit novel properties compared to established shape descriptors. J Chem Inf Model (2009) 0.93
Protein pockets: inventory, shape, and comparison. J Chem Inf Model (2010) 0.88
In silico toxicology - non-testing methods. Front Pharmacol (2011) 0.88
Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans. Bioorg Med Chem (2011) 0.88
A leap into the chemical space of protein-protein interaction inhibitors. Curr Pharm Des (2012) 0.86
Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem (2014) 0.85
Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. BMC Clin Pathol (2014) 0.85
Relating the shape of protein binding sites to binding affinity profiles: is there an association? BMC Struct Biol (2010) 0.80
A monoclonal antibody against human MUDENG protein. Monoclon Antib Immunodiagn Immunother (2013) 0.79
Protein pocket and ligand shape comparison and its application in virtual screening. J Comput Aided Mol Des (2013) 0.79
Ultrafast protein structure-based virtual screening with Panther. J Comput Aided Mol Des (2015) 0.79
Molecular dynamics study of naturally existing cavity couplings in proteins. PLoS One (2015) 0.77
Medicinal chemistry for 2020. Future Med Chem (2011) 0.76
Virtual target screening: validation using kinase inhibitors. J Chem Inf Model (2012) 0.76
USR-VS: a web server for large-scale prospective virtual screening using ultrafast shape recognition techniques. Nucleic Acids Res (2016) 0.76
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc (1988) 6.41
DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des (2001) 4.54
Automated docking of substrates to proteins by simulated annealing. Proteins (1990) 4.49
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med (2001) 3.45
Comparison of shape-matching and docking as virtual screening tools. J Med Chem (2007) 3.09
"Soft docking": matching of molecular surface cubes. J Mol Biol (1991) 2.19
Molecular Recognition of Proteinminus signLigand Complexes: Applications to Drug Design. Chem Rev (1997) 2.01
Shape complementarity at the hemoglobin alpha 1 beta 1 subunit interface. Biopolymers (1986) 1.95
Comparison of topological, shape, and docking methods in virtual screening. J Chem Inf Model (2007) 1.89
Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. J Med Chem (1996) 1.85
Ultrafast shape recognition to search compound databases for similar molecular shapes. J Comput Chem (2007) 1.84
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol (2007) 1.77
Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol (2005) 1.55
Similarity-based approaches to virtual screening. Biochem Soc Trans (2003) 1.45
Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem (2003) 1.39
PUZZLE: a new method for automated protein docking based on surface shape complementarity. J Mol Biol (1994) 1.37
Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol (2005) 1.33
Travel depth, a new shape descriptor for macromolecules: application to ligand binding. J Mol Biol (2006) 1.24
Making carbon-nitrogen bonds in biological and chemical synthesis. Nat Chem Biol (2006) 1.22
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
Drugs in other drugs: a new look at drugs as fragments. Drug Discov Today (2006) 1.19
An extension of spherical harmonics to region-based rotationally invariant descriptors for molecular shape description and comparison. J Mol Graph Model (2007) 1.14
Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14
QSD quadratic shape descriptors. 2. Molecular docking using quadratic shape descriptors (QSDock). Proteins (2000) 1.13
Selection of molecules based on shape and electrostatic similarity: proof of concept of "electroforms". J Chem Inf Model (2007) 1.11
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Prospective identification of biologically active structures by topomer shape similarity searching. J Med Chem (1999) 1.06
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Chemometric analysis of ligand receptor complementarity: identifying Complementary Ligands Based on Receptor Information (CoLiBRI). J Chem Inf Model (2006) 1.06
Crystal structure of a cocaine-binding antibody. J Mol Biol (2001) 1.03
Integration of fragment screening and library design. Drug Discov Today (2007) 1.01
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Enrichment of ligands for the serotonin receptor using the Shape Signatures approach. J Chem Inf Model (2005) 1.00
Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat Rev Drug Discov (2008) 1.00
Fast 3D shape screening of large chemical databases through alignment-recycling. Chem Cent J (2007) 1.00
Shapes of antibody binding sites: qualitative and quantitative analyses based on a geomorphic classification scheme. J Org Chem (2006) 0.98
A new class of molecular shape descriptors. 1. Theory and properties. J Chem Inf Comput Sci (2002) 0.95
Three-dimensional computation of atom depth in complex molecular structures. Bioinformatics (2005) 0.93
Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common receptor microdomain. Mol Pharmacol (2004) 0.92
Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J Med Chem (2007) 0.92
Tracking the chiral recognition of adsorbed dipeptides at the single-molecule level. Angew Chem Int Ed Engl (2007) 0.91
Fast, sensitive and cost-effective detection of nerve agents in the gas phase using a portable instrument and an electrochemical biosensor. Anal Bioanal Chem (2007) 0.91
Three-dimensional structure-activity relationship modeling of cocaine binding to two monoclonal antibodies by comparative molecular field analysis. J Mol Biol (2003) 0.90
Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques. J Med Chem (2006) 0.90
New quantum mechanics-based three-dimensional molecular descriptors for use in QSSR approaches: application to asymmetric catalysis. J Chem Inf Model (2007) 0.90
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos (2006) 0.89
Identification of previously unrecognized antiestrogenic chemicals using a novel virtual screening approach. Chem Res Toxicol (2006) 0.89
Fast and efficient in silico 3D screening: toward maximum computational efficiency of pharmacophore-based and shape-based approaches. J Chem Inf Model (2007) 0.88
Distance geometry approach to rationalizing binding data. J Med Chem (1979) 0.88
A novel shape-feature based approach to virtual library screening. J Chem Inf Comput Sci (2002) 0.88
Multi-dimensional QSAR in drug discovery. Drug Discov Today (2007) 0.86
The use of bioisosteric groups in lead optimization. Curr Opin Drug Discov Devel (2001) 0.84
Electronic van der Waals surface property descriptors and genetic algorithms for developing structure-activity correlations in olfactory databases. J Chem Inf Comput Sci (2003) 0.84
Specificity of substrate recognition by Pseudomonas fluorescens N3 dioxygenase. The role of the oxidation potential and molecular geometry. J Biol Chem (1997) 0.83
Molecules within molecules: recognition through self-assembly. Proc Natl Acad Sci U S A (2002) 0.83
Evaluation of a novel shape-based computational filter for lead evolution: application to thrombin inhibitors. J Med Chem (2002) 0.82
Novel approach to structure-based pharmacophore search using computational geometry and shape matching techniques. J Chem Inf Model (2008) 0.82
Similarity-based descriptors (SIBAR)--a tool for safe exchange of chemical information? J Comput Aided Mol Des (2005) 0.82
Using ensembles to classify compounds for drug discovery. J Chem Inf Comput Sci (2003) 0.82
Bioisosterism as a molecular diversity descriptor: steric fields of single "topomeric" conformers. J Med Chem (1996) 0.81
New developments in PEST shape/property hybrid descriptors. J Comput Aided Mol Des (2003) 0.81
2D QSAR and similarity studies on cruzain inhibitors aimed at improving selectivity over cathepsin L. Bioorg Med Chem (2007) 0.80
Transferable atom equivalent multicentered multipole expansion method. J Comput Chem (2003) 0.79
Molecular van der Waals space and topological indices from the distance matrix. Molecules (2004) 0.78
Path-space ratio as a molecular shape descriptor of polymer conformation. J Chem Inf Comput Sci (2003) 0.78
Bacterial ribonuclease P reaction is affected by substrate shape and magnesium ion concentration. Nucleic Acids Res Suppl (2003) 0.77
Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands. Eur J Med Chem (2002) 0.77
Partial molecular alignment via local structure analysis J Chem Inf Comput Sci (2000) 0.76
A comparison of field-based similarity searching methods: CatShape, FBSS, and ROCS. J Chem Inf Model (2008) 0.76
A general QSAR for dihydrofolate reductase inhibition by 2,4-diaminotriazines based upon molecular shape analysis. Arch Biochem Biophys (1981) 0.76
The centroidal algorithm in molecular similarity and diversity calculations on confidential datasets. J Comput Aided Mol Des (2005) 0.76
Educating medical students in laboratory medicine: a proposed curriculum. Am J Clin Pathol (2010) 3.18
A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol Lett (2005) 1.71
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today (2011) 1.45
Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today (2009) 1.40
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. Drug Discov Today (2012) 1.39
POSITIVE TEST FOR ANTITHYROGLOBULIN ANTIBODIES DUE TO ADMINISTRATION OF IMMUNOGLOBULIN REPLACEMENT THERAPY IN A PATIENT WITH THYROID CANCER. Endocr Pract (2015) 1.38
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res (2009) 1.37
Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab (2006) 1.32
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics (2008) 1.27
Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm (2009) 1.26
Mobile apps for chemistry in the world of drug discovery. Drug Discov Today (2011) 1.26
Methods for predicting human drug metabolism. Adv Clin Chem (2007) 1.24
A quality alert and call for improved curation of public chemistry databases. Drug Discov Today (2011) 1.22
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol (2007) 1.17
A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis (2012) 1.16
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14
Reaching out to collaborators: crowdsourcing for pharmaceutical research. Pharm Res (2010) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. Am J Respir Cell Mol Biol (2008) 1.13
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med (2009) 1.12
Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem. BMC Clin Pathol (2012) 1.11
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol (2003) 1.08
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther (2012) 1.07
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today (2013) 1.07
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Discov Today (2012) 1.05
Diversity of bile salts in fish and amphibians: evolution of a complex biochemical pathway. Physiol Biochem Zool (2010) 1.04
Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J Pharmacol Toxicol Methods (2009) 1.04
Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04
Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties. Drug Metab Dispos (2010) 1.04
Time for cooperation in health economics among the modelling community. Pharmacoeconomics (2010) 1.04
Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol (2009) 1.01
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther (2005) 1.01
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99
Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol (2008) 0.99
Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas. Proc Natl Acad Sci U S A (2007) 0.98
PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res (2004) 0.98
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97
Parallel worlds of public and commercial bioactive chemistry data. J Med Chem (2014) 0.97
Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev (2002) 0.97
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96
Functional evolution of the pregnane X receptor. Expert Opin Drug Metab Toxicol (2006) 0.96
Redefining Cheminformatics with Intuitive Collaborative Mobile Apps. Mol Inform (2012) 0.96
A rapid analysis of plasma/serum ethylene and propylene glycol by headspace gas chromatography. Springerplus (2013) 0.95
Comprehensive computational assessment of ADME properties using mapping techniques. Curr Drug Discov Technol (2005) 0.95
Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis. Pharm Res (2012) 0.94
Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res (2007) 0.94
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol (2010) 0.93
Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. J Chem Inf Model (2013) 0.93
Toxicology laboratory analysis and human exposure to p-chloroaniline. Clin Toxicol (Phila) (2009) 0.93
Drug monitoring: simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetam. J Chromatogr Sci (2007) 0.92
Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos (2010) 0.92
Intrinsic disorder in nuclear hormone receptors. J Proteome Res (2008) 0.92
Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen (2002) 0.91
Resident training in clinical chemistry. Clin Lab Med (2007) 0.91
Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev (2002) 0.90
Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm (2010) 0.90
Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res (2006) 0.90
Reengineering the pharmaceutical industry by crash-testing molecules. Drug Discov Today (2005) 0.90
Computational models for neglected diseases: gaps and opportunities. Pharm Res (2013) 0.89
Troubleshooting computational methods in drug discovery. J Pharmacol Toxicol Methods (2010) 0.89
The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. BMC Biochem (2011) 0.89
Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos (2004) 0.88
Molecular characterization of CYP2B6 substrates. Curr Drug Metab (2008) 0.88
Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res (2008) 0.88
A retrospective randomized study of asthma control in the US: results of the CHARIOT study. Curr Med Res Opin (2008) 0.87
Microbial biotransformations of bile acids as detected by electrospray mass spectrometry. Adv Nutr (2013) 0.87
Evolutionary diversity of bile salts in reptiles and mammals, including analysis of ancient human and extinct giant ground sloth coprolites. BMC Evol Biol (2010) 0.87
The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos (2009) 0.87
Alternative business models for drug discovery. Drug Discov Today (2011) 0.87
Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol Pharmacol (2013) 0.87
Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies. Biochem Pharmacol (2010) 0.86
Why open drug discovery needs four simple rules for licensing data and models. PLoS Comput Biol (2012) 0.86
Modeling of active transport systems. Adv Drug Deliv Rev (2002) 0.86
Computational prediction and validation of an expert's evaluation of chemical probes. J Chem Inf Model (2014) 0.84
Predicting inhibitors of acetylcholinesterase by regression and classification machine learning approaches with combinations of molecular descriptors. Pharm Res (2009) 0.84
Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Clin Chem (2009) 0.83
Computational mapping tools for drug discovery. Drug Discov Today (2009) 0.83
Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies. Biochem Pharmacol (2010) 0.83
Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier. Drug Metab Dispos (2013) 0.83
Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos (2002) 0.83
Classification of metabolites with kernel-partial least squares (K-PLS). Drug Metab Dispos (2006) 0.82
Analysis of vitamin D status at two academic medical centers and a national reference laboratory: result patterns vary by age, gender, season, and patient location. BMC Endocr Disord (2013) 0.82
Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays. Ther Drug Monit (2009) 0.82
Halogenated ligands and their interactions with amino acids: implications for structure-activity and structure-toxicity relationships. J Mol Graph Model (2008) 0.82